Diasorin
DiaSorin SpA is an Italian multinational biotechnology company engaged in the research, development, manufacturing, and commercialization of immunodiagnostic and molecular diagnostic test solutions. The company produces fully automated diagnostic analyzers, reagent kits, molecular assays, and specialized diagnostic tests used in clinical laboratories and hospitals worldwide. Its diagnostic product portfolio targets infectious diseases, bone and mineral metabolism, endocrinology, autoimmunedisorders, and oncology diagnostics. Principal revenue is derived from the direct commercial sale of proprietary diagnostic reagent kits and molecular assays, capital equipment sales, analyzer leases, and technical service support agreements. DiaSorin holds a leading global position in immunodiagnostics, recognized for its proprietary LIAISON analyzer platform and specialized clinical assay menu. Headquartered in Saluggia, Italy, the company's common stock is publicly listed and traded on Borsa Italiana under the ticker DIA.
9 of the funds FundTelligence covers report a position in Diasorin.
- Sector
- Health Care
- Country
- Italy
- Funds holding it
- 9
Funds holding Diasorin
- Nordea European Small and Mid Cap Sustainable Stars — Nordea Funds · 0.67 % (full portfolio disclosed, July 2026)
- Handelsbanken Europa SMB — Handelsbanken · 0.33 % (full portfolio disclosed, October 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.18 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.04 % (full portfolio disclosed, September 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.03 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.02 % (partially disclosed portfolio, June 2026)
- Storebrand Europa Plus — Storebrand · 0.0 % (full portfolio disclosed, October 2026)
- Storebrand Europa — Storebrand · 0.0 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 9 funds holding it.